Vivimed Labs (BOM:532660) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532660 Vivimed Labs Ltd BOM:532660
34 GF Score
Price ₹5.51
GF Value ₹2.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vivimed Labs FFO?

FFO (Funds from operations) only applies to REITs.

BOM:532660
34GF Score
Vivimed Labs Ltd BOM:532660
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vivimed Labs (BOM:532660) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.51 is trading 132.5% above its estimated GF Value™ of ₹2.37. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for BOM:532660:

  • FFO:
  • GF Value™: ₹2.37 vs. price of ₹5.51 (132.5% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the BOM:532660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges VIVIMEDLAB:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based pharmaceutical and specialty chemicals company. Its operations span active pharmaceutical ingredients (APIs), intermediates, nutraceutical ingredients, contract development and manufacturing (CDMO) of finished dosage formulations, specialty chemicals, and retail branded formulations. The company reports three segments: Specialty Chemicals, Pharma, and Others, with the Pharma business generating the majority of revenue. Vivimed serves pharmaceutical, personal care, and industrial customers, supplying both generic and custom-manufactured ingredients and formulations. It operates manufacturing facilities in India and maintains international operations, including subsidiaries in Europe and the United States, giving it a presence in regulated and emerging markets. Revenue is derived from product sales of APIs, formulations, and specialty chemicals, as well as contract manufacturing services for third parties. The company has faced financial and operational challenges in recent years, including insolvency proceedings involving certain lenders.
34GF Score

Get the complete analysis for BOM:532660

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.51
Price
₹2.37
GF Value